QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

Johnson & Johnson (NYSE: JNJ) reported a profit that exceeded estimates and raised its full-year forecast, but its stock is on track for its worst day since April 2025, with shares down approximately 6% to around $248. The decline is attributed to underperformance in its MedTech unit, which saw sales rise 2.5% to $8.64 billion, falling short of the $8.71 billion expected by analysts. CFO Joe Wolk noted that new drug deals will negatively impact 2027 adjusted earnings by $1.36 per share.